Advertisement

Introduction

  • Sevgi O. AralEmail author
  • Kevin A. Fenton
  • Judith A. Lipshutz
Chapter

Abstract

Sexually Transmitted Infections (STI), including HIV, remain among the most prevalent and costly health conditions facing western industrialized countries. In the United States alone, more than 19 million STIs are believed to occur each year, costing approximately $17 billion in diagnosis, treatment, and care costs [1, 2]. In Europe there are more than two million people living with HIV, and in 2010, 27,116 newly diagnosed HIV infections were reported across the European Union and the European Economic Area (EU/EEA) [3]. As with the US, the STI epidemics are remarkably distinct in individual countries. While some conditions such as chlamydia and the viral STIs are highly prevalent and demonstrate patterns consistent with generalized epidemics, STIs overall continue to disproportionally affect certain key populations, in particular men who have sex with men (MSM), persons originating from countries with generalized HIV epidemics and people who inject drugs. In many industrialized settings, governments continue to struggle with bringing these epidemics under control as they face stable or increasing HIV/STI rates among MSM, high prevalence of undiagnosed infection among young people, and poor coverage of treatment, care, and vaccination services for at-risk populations.

Keywords

Sexual Health Sexually Transmit Infection Human Immunodeficiency Virus Prevention European Economic Area Sexually Transmit Infection Prevention 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    CDC. Sexually transmitted disease surveillance 2010. Atlanta: U.S. Department of Health and Human Services; 2011. http://www.cdc.gov/std/stats10/surv2010.pdf.Google Scholar
  2. 2.
    Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health. 2004;36(1):11–9. http://www.guttmacher.org/pubs/journals/3601104.html.CrossRefPubMedGoogle Scholar
  3. 3.
    European Centre for Disease Prevention and Control/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2010. Stockholm: European Centre for Disease Prevention and Control; 2011. http://ecdc.europa.eu/en/publications/Publications/111129_SUR_Annual_HIV_Report.pdf.Google Scholar
  4. 4.
    Terris M. The changing face of public health. J Public Health. 1959;49:1113–9.CrossRefGoogle Scholar
  5. 5.
    Sanders BS. Local health department. Growth or Illusion? Public Health Rep. 1959;74:13–20.CrossRefPubMedGoogle Scholar
  6. 6.
    Ncayiyana D, Goldstein G, Goon E, Yach D. WHO: New public health and WHO’s ninth general program of work: a discussion paper. Geneva: World Health Organization; 1995.Google Scholar
  7. 7.
    Preventing Chronic Disease: the New Public Health. Robert Wood Johnson Foundation. Issue Brief Sept 2011. http://www.allhealth.org/publications/Public_health/Preventing_Chronic_Disease_New_Public_Health_108.pdf
  8. 8.
    Blanchard JF, Aral SO. Program science: an initiative to improve the planning, implementation and evaluation of HIV/sexually transmitted infection prevention programmes. Sex Transm Infect. 2011;87(1):2–3.CrossRefPubMedGoogle Scholar
  9. 9.
    Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomized trial. Lancet. 2007;369(9562):657–66.CrossRefPubMedGoogle Scholar
  10. 10.
    Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Med. 2005;2:e298.CrossRefPubMedGoogle Scholar
  11. 11.
    Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomized controlled trial. Lancet. 2007;369:643–56.CrossRefPubMedGoogle Scholar
  12. 12.
    Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of Tenofovir Gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996)):1168–74.CrossRefPubMedGoogle Scholar
  13. 13.
    Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedGoogle Scholar
  14. 14.
    Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.CrossRefPubMedGoogle Scholar
  15. 15.
    Padian NS, McCoy SI, Abdool Karim SS, et al. HIV prevention transformed: the new prevention research agenda. Lancet. 2011;378(9787):269–78.CrossRefPubMedGoogle Scholar
  16. 16.
    Aral SO, Lipshutz JA, Douglas JM. Introduction. In: Aral SA, Douglas JM Jr., editors, Lipshutz JA (assoc. editor). Behavioral interventions for prevention and control of sexually transmitted diseases. New York: Springer Science+Business Media, LLC; 2007. p. ix–xix.Google Scholar
  17. 17.
    Hawe P, Shiell A, Riley T. Theorising interventions as events in systems. Am J Community Psychol. 2009;43:267–76.CrossRefPubMedGoogle Scholar
  18. 18.
    Aral SO, Blanchard J. The Program Science Initiative: improving the planning, implementation and evaluation of HIV/STI prevention programs. Sex Transm Infect. 2012;88(3):157–9.CrossRefPubMedGoogle Scholar
  19. 19.
    President’s Emergency Plan for AIDS Relief (PEPFAR) prevention guidance. http://www.pepfar.gov.
  20. 20.
    Kaiser Family Foundation. Innovative financing mechanisms for Global Health: Overview & Considerations for U.S. Government Participation. U.S. Global Health Policy, Published online: 19 Oct 2011. http://www.kff.org/globalhealth/upload/8247.pdf
  21. 21.
    Monroe JA. Exploring the context. Am J Prev Med. 2011;41(4S3):S155–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Nagelkerke NJD, Jha P, de Vlas SJ, Korenromp EL, Moses S, Blanchard JF, Plummer FA. Modelling HIV/AIDS epidemics in Botswana and India: impact of interventions to prevent transmission. Bull World Health Organ. 2002;80:89–96.PubMedGoogle Scholar
  23. 23.
    Williams B, Wood R, Dukay V, et al. Treatment as prevention: preparing the way. J Int AIDS Soc. 2011;14 Suppl 1:S6.CrossRefPubMedGoogle Scholar
  24. 24.
    Granich RM, Gilks CF, Dye C, DeCock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57.CrossRefPubMedGoogle Scholar
  25. 25.
    Granich R, Gupta S, Suthar A, et al. ART in prevention of HIV and TB: update on current research efforts. Curr HIV Res. 2011;9(6):446–69.CrossRefPubMedGoogle Scholar
  26. 26.
    Stringer EM, Chi BH, Chintu N, et al. Monitoring effectiveness of programmes to prevent mother-to-child HIV transmission in lower-income countries. Bull World Health Organ. http://www.who.int/­bulletin/volumes/86/1/07-043117/en/
  27. 27.
    Barker PM, Mphatswe W, Rollins N. Antiretroviral drugs in the cupboard are not enough: the impact of health systems’ performance on mother-to-child transmission of HIV. J Acquir Immune Defic Syndr. 2011;56(2):e45–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Aral SO, Blanchard JF, Lipshutz JA. STD/HIV prevention intervention: efficacy, effectiveness and population impact. Sex Transm Infect. 2008;84(Suppl II):ii1–3.CrossRefPubMedGoogle Scholar
  29. 29.
    Shakarishvili G, Atun R, Berman P, et al. Converging health systems frameworks: towards a concepts-to-actions roadmap for health systems strengthening in low and middle income countries. Global Health Governance 2010;III(2) http://www.ghgj.org
  30. 30.
    Responding to the HIV/AIDS epidemic through health systems strengthening efforts. http://www.healthsystems2020.org/section/topics/hiv.
  31. 31.
    Thomas J, Curtis S, Smith J. The broader context of implementation science. J Acquir Immune Defic Syndr. 2011;58(1):e19–21.CrossRefPubMedGoogle Scholar
  32. 32.
    Padian N, Holmes C, McCoy S, et al. Response to ­letter from Thomas et al critiquing “Implementation science for the US President’s Emergency Plan for AIDS Relief”. J Acquir Immune Defic Syndr. 2011;58(1):e21–2.CrossRefGoogle Scholar
  33. 33.
    Chen MI, Ghani AC. Republished paper: populations and partnerships: insights from metapopulation and pair models into the epidemiology of gonorrhea and other sexually transmitted infections. Sex Transm Infect. 2010;86(Suppl III):iii63–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Leichliter JS, Chesson HW, Sternberg M, Aral SO. The concentration of sexual behaviours in the USA: a closer examination of subpopulations. Sex Transm Infect. 2010;86(Suppl III):iii45–51.CrossRefPubMedGoogle Scholar
  35. 35.
    Chesson HW, Sternberg M, Leichliter JS, Aral SO. The distribution of chlamydia, gonorrhea and syphilis cases across states and countries in the USA, 2007. Sex Transm Infect. 2010;86(Suppl III):iii52–7.CrossRefPubMedGoogle Scholar
  36. 36.
    Chesson HW, Sternberg M, Leichliter JS, Aral SO. Changes in the state-level distribution of primary and secondary syphilis in the USA, 1985–2007. Sex Transm Infect. 2010;86(Suppl III):iii58–62.CrossRefPubMedGoogle Scholar
  37. 37.
    Tanser F, Bärnighausen T, Cooke GS, Newell M-L. Localized spatial clustering of HIV infections in a widely disseminated rural South African epidemic. Int J Epidemiol. 2009;38(4):1008–16.CrossRefPubMedGoogle Scholar
  38. 38.
    Aral SO. Defining coverage: the importance of ­context. Presented at 6th IAS conference on HIV pathogenesis treatment and prevention, Rome, Italy, July 2011.Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Sevgi O. Aral
    • 1
    Email author
  • Kevin A. Fenton
    • 2
  • Judith A. Lipshutz
    • 3
  1. 1.Division of STD PreventionCenters for Disease Control and PreventionAtlantaUSA
  2. 2.NCHHSTP, Centers for Disease Control and PreventionAtlantaUSA
  3. 3.OSTLTS, Centers for Disease Control and PreventionAtlantaUSA

Personalised recommendations